CALR and myeloproliferative neoplasm: Consistently, MPN patients characterized by aberrant CRT not only display higher plasma levels of soluble CRT than healthy donors but, more interestingly, the mutated protein significantly reduces the phagocytosis of CRT-exposing cells.